Karin Eastham
Independent Chair of the BoardMs. Karin Eastham, C.P.A., M.B.A., has been an Independent Director of Veracyte, Inc. since December 2012, has been an Independent Director of Personalis, Inc. since September 9, 2019 and serves as its Chairman of the Board since May 17, 2022. She had been an Independent Director of Nektar Therapeutics since September 26, 2018 until June 08, 2023. Ms. Eastham served as the Chief Operating Officer and Executive Vice President of Burnham Institute for Medical Research from May 2004 to September 2008. Ms. Eastham has experience in financial and operations management, primarily in life sciences companies. She served as Senior Vice President of Finance, Chief Financial Officer and Secretary at Verenium Corporation from May 1999 to May 14, 2004 and served as its Principal Accounting Officer until May 14, 2004 and Consultant since May 14, 2004. From April 1999 to May 2004, Ms. Eastham served as Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She served as Vice President of Finance & Administration and Chief Financial Officer of Deltagen Research Laboratories, L.L.C. from April 1997 to April 1999. Ms. Eastham held similar positions with CombiChem, Inc. and Cytel Corporation. Prior to joining CombiChem Inc., she served as the Vice President of Finance and Administration and Chief Financial Officer at Cytel Corp., from October 1992 to April 1997. She served as the Vice President of Finance and Administration at Pritsker Corporation from May 1990 to October 1992. She held several positions, including Vice President of Finance at Boehringer Mannheim Corp., from June 1976 to August 1988 and its Chief Finance Officer. She served as an Independent Director of Genoptix, Inc. since July 30, 2008 until March 2011. Ms. Eastham had been an Independent Director of Geron Corporation since March 30, 2009 until 2023 and had been its Lead Independent Director since December 27, 2018 until 2023. She served as an Independent Director of Illumina Inc. from July 2004 to May 29, 2019. She has been a Director of Ipsen Biopharmaceuticals, Inc. since December 2003. She served on the boards of Directors of lllumina, Inc., from August 2004 to May 2019. She serves as a Director for Oncosis and Oncosis LLC. She served as a Director of Trius Therapeutics, Inc. from November 2009 to September 2013 and Amylin Pharmaceuticals Inc. since September 28, 2005 until August 2012. She served as a Director of MorphoSys AG from May 2012 to May 2017. She served as Member of Supervisory Board at Morphosys AG from May 31, 2012 to May 17, 2017. She serves on the boards of Directors of several life sciences companies. She served as a Director of AltHeadx, Inc. since September 2014 and Tercica Inc. since December 2003 until October 2008. She served as a Director of SGX Pharmaceuticals Inc. since August 2005; She served as a Director of Cyntellect Inc. She served as a Director of Molecular Probes Inc. and Salmedix Inc. since March 2004. She served as a Member of the Board of Trustees at Burnham Institute from May 2004 to September 2008. She is Certified Director and Certified Public Accountant. She holds a B.S. Degree in Accounting in 1973 and an M.B.A. in 1979 from Indiana University.
公司職務
- 公司名稱Personalis, Inc.股票代碼PSNL職務Independent Chair of the Board共事同僚
- CMChristopher M. HallCEO & Director
- KEKarin EasthamIndependent Chair of the Board
- RCRichard ChenPresident & Chief Medical Officer
- ALAaron L. TachibanaCFO & COO
- RBRuss B. AltmanCo-Founder and Member of Clinical & Scientific Advisory Board
- EAEuan Angus AshleyCo-Founder and Member of Clinical & Scientific Advisory Board
- MPMichael P. SnyderCo-Founder and Member of Clinical & Scientific Advisory Board
- 公司名稱Veracyte, Inc.股票代碼VCYT職務Independent Director共事同僚
- MAMarc A. StapleyCEO & Director
- RSRobert S. EpsteinIndependent Chair
- RCRebecca ChambersExecutive VP & CFO
- PGPhillip G. FebboChief Scientific & Medical Officer
- AMAnnie McGuireExecutive VP, General Counsel & Head of Market Access
- JLJohn LeiteGlobal Chief Commercial Officer
- EJEvan JonesIndependent Director
- JHJens H. HolsteinIndependent Director
